Gene therapies for inherited skin disorders.

[junctional epidermolysis bullosa]

Skin is an amenable organ for gene replacement and gene editing therapeutics . Its accessibility makes it well-suited for direct topical gene delivery , grafting of genetically corrected cells , and monitoring of possible adverse events . Monogenic recessive disorders with a clinically severe or life-threatening phenotype provide the best candidate diseases for the introduction of a single normal copy of the gene into the target cell , usually keratinocytes . Preclinical studies have shown impressive results in terms of gene correction using both in vivo and ex vivo approaches . The clinical application of gene replacement or genomic editing as potential therapies for inherited skin disorders , however , has been held back by the inadequacy of delivery vectors and concerns from regulatory agencies regarding safety ; thus translation to clinical trials has been slow . Over the past 15 years , cell culture and animal models have shown efficient gene correction techniques as preludes to treat inherited skin disorders such as junctional epidermolysis bullosa , dystrophic epidermolysis bullosa , xeroderma pigmentosum , lamellar ichthyosis and Netherton syndrome , but so far only one patient has been treated in a clinical trial . This article reviews the current status of gene therapies for patients with inherited skin diseases and explores future perspectives .

Diseases
Validation

Diseases presenting "usually keratinocytes" symptom

dystrophic epidermolysis bullosa

junctional epidermolysis bullosa

lamellar ichthyosis

You can validate or delete this automatically detected symptom